Pomalidomide-PEG2-Tos is primarily utilized in the development of targeted cancer therapies. Its structure allows it to act as a linker in antibody-drug conjugates (ADCs), where it connects the cytotoxic drug to the antibody. This enables precise delivery of the drug to cancer cells, minimizing damage to healthy tissues. It is particularly effective in enhancing the stability and solubility of the conjugate, improving therapeutic outcomes. Additionally, it is used in research to study drug delivery mechanisms and optimize treatment strategies for various cancers, including multiple myeloma and other hematologic malignancies.